On Wednesday, Vir Biotechnology, Inc. (NASDAQ:VIR) presented initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, which targets a variety of HER2-expressing solid tumors, and VIR-5500, which targets PSMA in metastatic castration-resistant prostate cancer (mCRPC).
Data show encouraging preliminary safety and efficacy profiles with no dose-limiting cytokine release syndrome, maximum tolerated dose not yet reached as dose escalation continues, and early clinical response signals observed in heavily pretreated participants.
On Thursday, Morgan Stanley upgraded Vir Biotechnology, noting that “initial data provide early platform de-risking and see potential for activity to improve as dose escalation continues.”
Early …
Full story available on Benzinga.com